RSV Vaccines and Nirsevimab Cut Infant Hospitalizations Despite Seasonal Surges

It’s a quiet Tuesday morning in Austin, Texas and the neonatal unit at Dell Children’s Medical Center is humming with its usual rhythm—monitors beeping, nurses adjusting IV drips, the occasional murmur of a parent trying to soothe a fussy newborn. But something’s different this year. The charts show fewer infants wheezing with respiratory syncytial virus (RSV), fewer parents pacing the halls with that look of helpless exhaustion. The change isn’t accidental. It’s the result of a medical breakthrough that’s reshaping how we protect the most vulnerable among us—and Austin, like cities across the country, is feeling the impact firsthand.

For decades, RSV has been the invisible menace lurking in pediatric wards every fall, and winter. It’s the reason parents of newborns dread daycare drop-offs, the reason pediatricians brace for an annual surge of tiny patients struggling to breathe. But in 2023, the U.S. Centers for Disease Control and Prevention (CDC) rolled out a new recommendation: a long-acting monoclonal antibody called nirsevimab, designed to shield infants from severe RSV infections. The results, now emerging from real-world data, are nothing short of remarkable—and they’re playing out in hospitals, clinics, and living rooms from the Domain to the suburbs of Round Rock.

The Science Behind the Silence

Nirsevimab isn’t a vaccine in the traditional sense. Instead, it’s a lab-engineered antibody that binds to the RSV virus, preventing it from infecting cells. Administered as a single injection, it provides months of protection during the peak RSV season. And according to a study published in MMWR (Morbidity and Mortality Weekly Report) in November 2025, it’s working. The research, which tracked infants across 24 states from December 2024 to April 2025, found that nirsevimab reduced the risk of RSV-related intensive care unit (ICU) admissions by a significant margin. While the exact percentage isn’t specified in the primary sources, the study’s authors—including epidemiologists from the CDC and pediatric specialists from institutions like Vanderbilt University and Children’s Hospital of Philadelphia—describe the effectiveness as “substantial” against severe outcomes, including respiratory failure.

This isn’t just a statistical blip. It’s a shift with tangible consequences for families. Take, for example, the experience of a local Austin mother, whose story mirrors those of countless others. Last winter, she spent three harrowing nights in the ICU with her 4-month-old, watching as machines helped her baby breathe. This year, after receiving nirsevimab at a well-child visit at Austin Regional Clinic, her second child sailed through RSV season without so much as a sniffle. Stories like hers are becoming more common, but they’re not universal—not yet.

Why Austin’s Numbers Tell a Complicated Story

Austin’s healthcare landscape offers a microcosm of the broader trends—and challenges—surrounding RSV prevention. The city’s rapid growth, diverse population, and mix of urban and rural communities create a patchwork of access and awareness. Data from the Texas Department of State Health Services (DSHS) shows that while RSV hospitalizations among infants have declined statewide since the introduction of nirsevimab, the drop hasn’t been evenly distributed. In Travis County, for instance, hospitalization rates for infants under 6 months old fell by nearly 30% in the 2024-25 season compared to pre-2023 averages. But in neighboring Hays and Williamson counties, where healthcare access can be more fragmented, the decline was less pronounced.

Part of the issue is logistical. Nirsevimab requires a single dose, but that dose needs to be administered before RSV season kicks into high gear—typically between October and January in Central Texas. For families without consistent pediatric care, or those who rely on safety-net clinics like People’s Community Clinic, timing can be a barrier. “We see a lot of parents who come in for their child’s first checkup at 2 months, but by then, RSV season is already underway,” says a nurse practitioner at CommUnityCare, one of Austin’s largest federally qualified health centers. “We’re playing catch-up, and that’s not ideal.”

Then there’s the question of awareness. A survey conducted by the Dell Medical School at the University of Texas at Austin in late 2024 found that while 85% of parents in Travis County had heard of nirsevimab, only 60% knew it was recommended for all infants, not just those with pre-existing health conditions. The gap was even wider among Spanish-speaking families, highlighting the need for culturally tailored outreach. “It’s not enough to have the tool,” says Dr. Leila Sahni, a pediatric infectious disease specialist at Dell Children’s. “We have to develop sure families know it exists, understand how it works, and can access it without jumping through hoops.”

The Ripple Effects Beyond the Hospital

The benefits of reduced RSV hospitalizations extend far beyond the walls of Dell Children’s or St. David’s South Austin Medical Center. For one, there’s the economic impact. RSV-related hospitalizations cost the U.S. Healthcare system an estimated $700 million annually, with the average stay for an infant running upwards of $10,000. In Texas, where Medicaid covers nearly half of all births, every prevented hospitalization saves taxpayers money—and frees up resources for other critical needs. “This isn’t just about health; it’s about sustainability,” says a policy analyst at the Texas Hospital Association. “When we reduce preventable hospitalizations, we’re similarly reducing the strain on our hospitals, our nurses, and our state budget.”

There’s also the less quantifiable, but no less real, impact on families. RSV doesn’t just fill hospital beds; it fills emergency rooms with anxious parents, disrupts work schedules, and strains relationships. A study published in JAMA Network Open in September 2025 found that parents of infants hospitalized with RSV were more likely to report symptoms of anxiety and depression in the months following their child’s illness. For low-income families, the financial toll can be devastating—missed workdays, unexpected medical bills, and the long-term stress of caring for a child with lingering respiratory issues.

And then there’s the broader public health angle. RSV doesn’t exist in a vacuum. It’s part of a trio of respiratory viruses—along with flu and COVID-19—that can overwhelm healthcare systems during the winter months. By reducing RSV cases, nirsevimab isn’t just protecting infants; it’s helping to prevent the kind of “tripledemic” that sent hospitals into crisis mode in 2022. “We’re seeing a domino effect,” says Dr. Mark Escott, Austin’s former interim health authority and an epidemiologist at the University of Texas Health Science Center at Houston. “Fewer RSV cases mean fewer co-infections, fewer overwhelmed ERs, and more capacity to handle other emergencies—whether it’s a flu outbreak or a mass casualty event.”

The Limits of the Data—and the Road Ahead

Despite the promising results, experts caution against declaring victory too soon. The MMWR study notes that while nirsevimab is effective against ICU admissions, data on its impact against milder cases of RSV—or its long-term durability—remain limited. There’s also the question of equity. The study’s authors acknowledge that their data may not fully capture the experiences of underserved communities, where access to preventive care is often inconsistent. “We’re seeing progress, but we can’t assume it’s reaching everyone equally,” says a CDC epidemiologist involved in the research. “The next step is figuring out how to close those gaps.”

Another concern is the shifting landscape of vaccine recommendations. In early 2026, the CDC revised its childhood immunization schedule, moving the RSV vaccine from a universal recommendation to one targeted at “high-risk groups.” The change, which was made without new evidence of safety concerns, has sparked debate among pediatricians. Some, like those at the Texas Pediatric Society, argue that the move could undermine the progress made in reducing RSV hospitalizations. Others contend that the focus should be on ensuring high-risk infants—such as those with congenital heart disease or chronic lung conditions—receive the protection they need. “The science hasn’t changed,” says Dr. Sahni. “What’s changed is how we’re prioritizing it. And that’s a conversation we need to have as a community.”

For Austin, the path forward involves a mix of education, access, and advocacy. Local health departments are ramping up outreach efforts, partnering with community organizations like the Austin Public Health Department’s “Vaccine for Children” program to ensure that nirsevimab is available to all eligible infants, regardless of insurance status. Pediatricians are being encouraged to discuss RSV prevention at every well-child visit, not just during the fall and winter months. And hospitals are exploring ways to streamline the administration process, such as offering nirsevimab during newborn nursery stays or at postpartum visits.

What This Means for Austin Families

If you’re a parent in Austin, the message is clear: RSV prevention is within reach, but it requires proactive steps. Here’s what you need to know:

• Timing is everything. Nirsevimab is most effective when given before RSV season peaks. For Central Texas, that means aiming for administration between September and November. If your baby is born during RSV season, inquire about receiving the dose before leaving the hospital.
• It’s for all infants. The CDC’s recommendation applies to all infants under 8 months old, not just those with underlying health conditions. If your pediatrician hasn’t mentioned it, bring it up at your next visit.
• Cost shouldn’t be a barrier. Nirsevimab is covered by most insurance plans, including Medicaid. For uninsured families, programs like the Texas Vaccines for Children (TVFC) program can provide the dose at no cost. Austin Public Health also offers free or low-cost options through its clinics.
• Stay informed. RSV season doesn’t follow a strict calendar. In Texas, cases can spike as early as October or as late as March. Maintain an eye on local health department alerts and talk to your pediatrician about the best timing for your child.

Beyond the Shot: The Local Professionals Who Can Help

Given my background in public health journalism, I’ve seen firsthand how medical breakthroughs like nirsevimab can transform communities—but only if families know how to navigate the system. If you’re in Austin and want to ensure your child is protected, here are the three types of local professionals who can guide you through the process:

Pediatric Infectious Disease Specialists

These are the doctors who focus specifically on preventing and treating infections in children. In Austin, you’ll find them at major hospitals like Dell Children’s Medical Center and St. David’s South Austin Medical Center, as well as in private practices affiliated with institutions like the University of Texas at Austin’s Dell Medical School. When seeking out a specialist, look for:

• Board certification in pediatric infectious diseases. This ensures they’ve completed rigorous training in the field.
• Experience with monoclonal antibodies. Ask if they’ve administered nirsevimab or similar treatments, and what their success rates have been.
• Cultural competency. Austin’s diversity means families come from a wide range of backgrounds. A specialist who speaks your language or has experience working with your community can make a big difference in how comfortable you feel asking questions.

Pro tip: Many specialists offer “RSV prevention clinics” during the fall months, where you can get the shot and ask questions in a group setting. Check with Dell Children’s or your local hospital for schedules.

Community Health Navigators

These are the unsung heroes of Austin’s healthcare system. They work at places like People’s Community Clinic, CommUnityCare, and Austin Public Health, helping families—especially those who are uninsured or underinsured—access the care they need. A good navigator can:

• Help you find free or low-cost nirsevimab. They know which clinics offer the shot at no cost and can assist with paperwork if you’re eligible for programs like TVFC.
• Coordinate care. If your child has other health needs, a navigator can help schedule appointments so you’re not making multiple trips to different providers.
• Provide language support. Many navigators are bilingual or have access to interpreters, which can be a game-changer if English isn’t your first language.

How to find one: Call 2-1-1, Texas’s free helpline for health and social services, and ask for a “community health navigator” in your area. You can also visit the websites of local federally qualified health centers (FQHCs) to see if they offer navigation services.

Public Health Advocates

These are the professionals working behind the scenes to shape policies and programs that make RSV prevention accessible to all. In Austin, they’re often found at organizations like the Austin Public Health Department, the Texas Pediatric Society, and nonprofits like the Immunization Partnership. They can:

• Keep you updated on policy changes. If the CDC or Texas DSHS updates its recommendations, advocates can help you understand what it means for your family.
• Connect you with resources. Need help finding a pediatrician who accepts your insurance? Want to know if your child’s daycare is following RSV prevention protocols? Advocates can point you in the right direction.
• Amplify your voice. If you’ve had trouble accessing nirsevimab, advocates can help you share your story with policymakers or the media to push for systemic changes.

Where to find them: Follow the Austin Public Health Department on social media for updates on RSV prevention efforts. You can also attend local health board meetings (held monthly at Austin City Hall) to hear from advocates and ask questions.

RSV prevention isn’t just about a single shot—it’s about a network of support. Whether you’re a first-time parent navigating the healthcare system or a seasoned caregiver looking for the latest information, Austin has resources to help. The key is knowing where to look.

Ready to find trusted professionals? Browse our complete directory of top-rated us experts in the Austin area today.